Classical end-points in clinical therapeutic trials in oncology are usually defined by total, recurrence-free or systemic disease-free survival. Primarily, these allow an adequate description of the biological course of the disease. In current oncological research advances in the treatment of cancer patients as measured by these end-points must realistically be assumed to be only of a rather small magnitude. This implies, on the one hand, that prospectively only by large-scale multicentre trials and retrospectively only by meta-analyses of comparable trials can sufficient numbers of patients be reached to allow a detection of treatment benefits of a realistic size. On the other hand, if treatments do not differ much with respect to survival, it is a plausible step forward to extend the classical criteria of assessing treatment efficacy. It is undisputed that the disease and its treatment have an influence on all aspects of a cancer patient's life. Although physicians had previously recorded the occurrence of toxic reactions possibly induced by cancer treatment, it was not until the 1940s that with their pioneering work Karnofsky et al. (1948) made a first attempt to quantify the performance status of patients with advanced cancer. In the following decades there has been increasing realisation of the need to achieve a more comprehensive evaluation of treatment efficacy beyond the objective aspects of achieving optimal survival, maximal tumour response and minimal toxicity (Maguire & Selby, 1989) . In attempting to reach this goal, additional end-points in cancer clinical trials were introduced that take into account the subjective response of the patients to their illness and its treatment. The sum of aspects of the patients' subjective well-being is most often caHled 'quality of life' (QoL) (e.g. Tchekmedyian & Cella, 1990 The second point of the QoL construct seems rather obvious, but it has taken some time to become accepted that, whenever possible, the individual patient is the principal authority to be asked about his/her QoL. Physician's assessment of the patients' QoL, which was widely practised when QoL methodology was introduced, has proved to be less reliable when used exclusively (Slevin et al., 1988; Regan et al., 1991) . It is undisputed that a detailed interview is the most appropriate approach to comprehensively evaluate an individual's well-being. However, the most feasible form of a measuring instrument in the context of multicentre trials is the self-administered questionnaire. A good questionnaire is characterised by possessing certain so-called 'psychometric' standards like validity (measuring what is intended to be measured), reliability (measuring with sufficient precision) and sensitivity (ability to detect changes).
The last is important especially in the light of point (3) Aaronson et al., 1993) . Their self-assent questionnaire is based on a modular approach always including a core questionnaire (QLQ-C30) comprising items related to general aspects of well-being which are deemed valid for a broad range of patients with different types of cancer. The QLQ-C30 includes five functional scales (physical, role, cognitive, emotional and social), three general symptom scales (fatigue, pain and nausea/ vomiting), several single-item symptom measures, one global health and one global quality-of-life item. The rating of each item is on either a two-or four-point scale using verbalised categories. The QLQ-C30 is supplemented by a module with tumour-specific items. A nine-item version for lung cancer patients has been developed, and others are to follow (Aaronson et al., 1988) . The main advantage of the modular approach is the possibility of allowing sensible comparisons of results between QoL trials on the basis of the same core questionnaire. These can also serve as a sound basis for performing meta-analyses of comparable QoL trials. In that sense the QLQ-C30 possesses the additional advantages of being conceptualised as an international cross-cultural measurng istrument that has been tested in 13 different countries and of having been developed specifically for use with cancer patients.
CoIectioel of QoL data
The assessment of QoL as an important end-point in cancer clinical trials will usually be performed paralkl to the recording of the classical clinical end-points. As a consequence the number of data to be coLected within a trial will inevitably increase. Therefore, especially in large multicentre tnals, the practicability of the QoL measuring instrument is of primary importance to achieve suffikient numbers of partwipating centres and patients. Although it may be tempting to gather as much information as possible to account for the multidimensional character of QoL, for reasons of feasibility the questionnaire should be kept as simple and short as possible. Bearing in mind the medical condition of the patient population it is desirable to concentrate on not more than 50 colloquially formulated questions that each patient can easily answer without assistance and within a short time.
Emphasis must be put on achieving acceptance of the importance of the QoL assessment among all the participating centres, because additional data collction introduces an extra burden for the medical staff. The participating clinicians should be convinced that the QoL assesment is not just a 'fashionable' add-on, but a serious end-point of a trial. Guidelines for the administering of the questionnaires that also include the rationale for the QoL assessment have proved helpful in this context.
QoL assessments should be tied in with the routine clinical follow-up schedule for the triaL which for avoidance of bias should be at the same times for all treatment arms. However, some flexibility with a preplanned time schedule may sometimes be appropriate. If, for example, in a chemotherapy trial a QoL assessment has been planned at some fixed time point corresponding to the regular end of treatment, but there have been delays in some patients because of toxic side-effects, it is better to defer the QoL assessment to the actual end of treatment in these patients instead of adhering to a rigid time frame. During the conduct of the trial, continuous monitoring of data quality and especially the patients' compliance with QoL assments is mandatory to enable immediate intervention in case of missing or incomplete data. One of the most severe sources of bias that may be introduced in a clinical trial is non-compliance of patients, either by dropping out of the trial completely or by refusing to participate in the QoL assessment. The magnitude of this bias will depend strongly on the reasons for dropping out. If, for example, advancing disease prevents patients participating in the QoL assessment, consideration of only the responding patients might lead to a too optimistic assessment of QoL in that trial. One might even thinkl of an extreme scenario of an ineffective treatment not preventing disease progression, and leading to a deterioration of patients' wellbeing, which the patients are no longer capable of documenting on a QoL form. Owing to their non-compliance these patients would not contribute to the analysis of QoL. Compared with a treatment that is effective but induces sideeffects that reduce the well-being, but not so severely that the patients refuse QoL assessment, an analysis based on the available QoL forms may falsely lead to declaring the worse treatment superior.
Generally, this bias can at best be reduced by using a short, clearly formulated questionnaire with ordinal, verbalised answer categories that can be completed without much additional effort in a short time. Within a multicentre clinical trial the practicability of the QoL assessment for the individual patient should be one of the major goals, being as important as the demand for psychometric properties of the questionnaire. Many patients do not regard feasible QoL assessment as an extra burden, but rather have a positive attitude to being questioned about their well-being (Aaronson et al., 1993) , which in itself may also positively influence the doctor-patient relationship.
An example of a trial that used QoL as a primary endpoint, but failed to produce statistically evaluable data, was published by Ganz et al. (1988) . In this randomised trial two treatments for metastatic lung cancer patients were compared using the functional living index of cancer (FLIC) as the QoL measure (Schipper et al., 1984 (Zee & Pater, 1991) and generalised linear models otherwise (Agresti, 1989) . Zwinderman (1990) presented a simple version of such a longitudinal model for the comparison of the effect of two different treatments on the QoL of breast cancer patients with bone metastases. From his QoL measurements he reduced each different aspect of QoL (mobility, toxicity, pain and psychological distress) to the binary outcome of 'good' or 'bad' QoL and proposed a model assuming that the probability of observing a patient in a 'good' QoL state at a certain point in time depends on a baseline level characterising the individual patient, a treatment effect and a time effect, the last two being assumed to be the same for all patients. For the functional relationship between the probability of having 'good' QoL and certain clinical covariates he used a logistic regression model.
A serious problem that occurs in a longitudinal analysis is missing QoL data for patients who have died or dropped out of the trial. There is no straightforward way to handle this problem, but it is obvious that not including these patients in an analysis is likely to lead to biased estimates. Zwinderman (1992) suggests imputing mean values, calculated from available patients, for missing values under the often unrealistic assumption that QoL data is missing at random.
In clinical oncological research principal interest centres around the times from diagnosis or randomisation to an end-point such as death or tumour relapse, and the data are analysed using techniques of survival analysis (e.g. Kaplan-Meier product limit estimate, Cox's proportional hazards regression model). From the viewpoint of survival analysis it seems appealing to combine length of survival, the classical end-point, and QoL into a single end-point, which is most often described as quality-adjusted life years (QUALY) or quality-adjusted survival (QAS). This can be defined by multiplying each period of the individual survival time by a weight corresponding to the patient's QoL during this period and then summing these weighted times. In this context recurrence-free survival time can be regarded a special case of a QAS with time from tumour removal until the time of first occurrence of a relapse receiving a weight of 1, and the time after relapse receiving a weight of 0. The most elaborate and interesting application of weighted survival times in clinical research has been presented by Gelber et al. (1986) by their definition of TWiST (time without symptoms and toxicity). For this purpose they subtracted from individual survival times of patients with advanced breast cancer those months in which the patient experienced or recovered from severe side-effects of local surgical procedures. This can also be considered as attaching a weight of 1 for those survival times a patient is both disease-free and not suffering from severe side-effects and 0 otherwise. Goldhirsch et al. (1989) later modified TWiST into Q-TWiST (quality-adjusted TWiST) allowing the attachment of positive weights between 0 and 1 to the survival times of a patient spent in toxicity and after recurrence. The choice of suitable weights that correspond to an adequate assessment of QoL is still the subject of controversial discussion.
An intuitive approach to analyse these QAS times would be an application of standard methods of survival analysis.
However, if censored observations are present, e.g. patients
have not yet reached the end-point of interest at the time of analysis, as is usual in survival data, the use of individually calculated QAS can lead to serious biases in the analysis. Glasziou et al. (1990) Cox's proportional hazards model has also been investigated for this situation (Cole et al., 1993) .
Co.ch.ioa and Ms cmNM
The formal assessment of QoL of cancer patients in addition to 'hard' clinical data is becoming more and more accepted in the medical community, as reflected for example in a recent editorial in the British Medical Jornal demanding that 'cancer trials should include measures of patients' well-being' (Byrne, 1992) . The interest in QoL is demonstrated by the increasing number of publications using QoL in the title or as a keyword. In a literature survey (Schumacher et al., 1991) (Kiebert et al., 1991) . This result at first seems rather surprising and counter to the often-stated contrary opinion. A possible explanation is that the negative effect that the cancer diagnosis produces on the patients' QoL overrides the effect of both surgical treatments.
Similar unexpected results were reported with respect to adjuvant treatment in cancer patients (Slevin, 1992) . It is well known that chemotherapy induces toxic side-effects in a large proportion of patients, with the intensity of some of the side-effects being proportional to the intensity of treatment. However, QoL studies have found that a more intensive treatment is not always associated with lower QoL despite the obj'ective occurrence of more severe side-effects. A possible explanation here is that the experience of going through a painful treatment provides more hope for a cure of the disease in some patients, leading to a better toleration of side-effects.
The results from these trials may serve as examples of the need to not just believe one's own assumptions about patients' QoL, but rather to let the patients assess their QoL themselves.
The successful implementation of a QoL assessment in large multicentre trials relies on the feasibility of the measurement approach. Short, self-administered, but validated questionnaires covering the major aspects of QoL should be used. The achievement of high-quality QoL data should be given the same priority as clinical data, because this is essential for adequate analysis and interpretation. Once a trial is completed, it will be impossible to improve poor data quality. Efforts to improve data quality, such as those mentioned, should be considered in the planning and implemented as part of the execution of a trial. It should be emphasised to all trial participants that the evaluation of QoL is more than just adding a new laboratory measurement. As Ganz et al. (1988) noted, 'it is critically important that QoL data are collected with the same care and detail as are response and toxicity data'.
In our literature survey (Schumacher et al., 1991) we reviewed the statistical methods used to analyse QoL data in published trials. About one-third of the publications presented solely a descriptive analysis of the data by reporting frequencies, means and correlations. In about 50% of the trials univariate parametric or non-parametric significance tests were applied and multiple P-values reported. Although QoL was measured at more than two points in time in about 40% of the publications, adequate methods to analyse QoL over time were rarely used.
Although it is preferable to keep statistical methods as simple as possible to allow an easy understanding of the results, the complicated structure of QoL data often requires sophisticated analyses. Using only elementary statistical procedures in situations where they are inadequate may yield easily understandable, but also wrong, conclusions. However, as the methods for assessing QoL become more sophisticated, greater emphasis must be put into 'translating' the numerical results into understandable information for clinicians and patients to broaden the knowledge base for future treatment decisions . For example, interpretation of the values of QoL scores calculated by an aggregation of different questions of a questionnaire may be easier when presented as the percentage of the maximum possible score instead of the raw values, and in addition makes the results more independent of the mostly arbitrary item scoring.
The proposal to combine quantity and quality of survival into one new end-point such as QAS seems intuitively appealing because end-points like total or recurrence-free survival can be regarded as special cases. It also helps to solve the problem of how to treat missing QoL data for those patients that have died. But weighting a 'hard' end-point with a 'soft' one does not create a new 'hard' end-point but rather a 'medium' one, still leaving a lot of controversy.
It is rather difficult to propose a standard statistical strategy to be adopted for an analysis of QoL data, because, unlike the situation in survival analysis, there is no typical kind of data set that calls for specific type of analysis. This is also the reason why papers concerned with the analysis of QoL data do not advocate fixed analysis plans (Schumacher et al., 1991; Zee & Pater, 1991; . Because of the inherent 'softness' of QoL data it might be sensible to offer more than one adequate analysis approach, enabling interested readers to perform a sensitivity analysis for themselves.
Assessing QoL in cancer patients has reached a sound basis. Much effort has recently been put into the propagation of the idea of including QoL measures routinely in clinical QUALITY OF LIFE ASSESSMENT 5 research (e.g. Fitzpatrick et al., 1992; Slevin, 1992; Spieglehalter et al., 1992; Finlay & Dunlop, 1994) , but still more efforts are needed in this direction. In our view, the field of QoL evaluation requires further intensive interdisciplinary collaboration of physicians, psychosocial researchers and biostatisticians.
